Immunotherapy for prostate cancer: Requirements for a successful regime transfer
Despite the revolutionary progress in cancer treatment using immune checkpoint inhibitors (ICIs), remarkable responses in prostate cancer treatment have not yet been achieved. The disappointing previous results of ICIs have required further studies towards combined treatment targeting other pathways...
Main Authors: | Seung-hwan Jeong, Cheol Kwak |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Urological Association
2022-01-01
|
Series: | Investigative and Clinical Urology |
Subjects: | |
Online Access: | https://icurology.org/pdf/10.4111/icu.20210369 |
Similar Items
-
A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy
by: Chenyu Mao, et al.
Published: (2021-11-01) -
New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer
by: Mingen Lin, et al.
Published: (2023-06-01) -
Inhibition of WHSC1 Allows for Reprogramming of the Immune Compartment in Prostate Cancer
by: Muzamil Y. Want, et al.
Published: (2021-08-01) -
Editorial: Immunotherapy for Prostate Cancer – turning the immunological desert into an oasis of hope
by: Christine Galustian, et al.
Published: (2022-09-01) -
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
by: Clara Martori, et al.
Published: (2022-01-01)